Alternative pre-mRNA splicing allows exons of pre-mRNA to be spliced in different arrangements to produce functionally distinct mRNAs. More than 95% of human genes encode splice isoforms, some of which exert antagonistic functions. Recent studies revealed that alterations of the splicing machinery can cause the development of neoplasms, and understanding the splicing machinery is crucial for developing novel therapeutic strategies for malignancies. Colorectal cancer patients need novel strategies not only to enhance the efficacy of the currently available agents but also to utilize newly identified therapeutic targets. This review summarizes the current knowledge about the splice isoforms of VEGFA, UGT1A, PXR, cyclin D1, BIRC5 (survivin), DPD, K-RAS, SOX9, SLC39A14 and other genes, which may be possible therapeutic targets for colorectal cancer. Among them, the VEGFA splice isoforms are classified into veGFAxxx and veGFAxxxb, which have proangiogenic and antiangiogenic properties, respectively; UGT1A is alternatively spliced into UGT1A1 and other isoforms, which are regulated by pregnane X receptor isoforms and undergo further splicing modifications. Recently, the splicing machinery has been extensively investigated and novel discoveries in this research field are being reported at a rapid pace. The information contained in this review also provides suggestions for how therapeutic strategies targeting alternative splicing can be further developed.
Alternative pre-mRNA splicing allows exons of pre-mRNA to be spliced in different arrangements to produce functionally distinct mRNAs. More than 95% of human genes encode splice isoforms, some of which exert antagonistic functions. Recent studies revealed that alterations of the splicing machinery can cause the development of neoplasms, and understanding the splicing machinery is crucial for developing novel therapeutic strategies for malignancies. Colorectal cancer patients need novel strategies not only to enhance the efficacy of the currently available agents but also to utilize newly identified therapeutic targets. This review summarizes the current knowledge about the splice isoforms of VEGFA, UGT1A, PXR, cyclin D1, BIRC5 (survivin), DPD, K-RAS, SOX9, SLC39A14 and other genes, which may be possible therapeutic targets for colorectal cancer. Among them, the VEGFA splice isoforms are classified into veGFAxxx and veGFAxxxb, which have proangiogenic and antiangiogenic properties, respectively; UGT1A is alternatively spliced into UGT1A1 and other isoforms, which are regulated by pregnane X receptor isoforms and undergo further splicing modifications. Recently, the splicing machinery has been extensively investigated and novel discoveries in this research field are being reported at a rapid pace. The information contained in this review also provides suggestions for how therapeutic strategies targeting alternative splicing can be further developed.
introduction
Colorectal cancer (CRC) is the third most common cancer worldwide and the second most common cause of cancer mortality; ~608 000 deaths are attributed to this disease annually (1) . As indicated in the National Comprehensive Cancer Network (NCCN) guidelines version 1.2013 (2), the anticancer agents used for CRC include 5-fluorouracil (5-FU), irinotecan hydrochloride (CPT-11), oxaliplatin and molecularly targeted agents such as bevacizumab, cetuximab and panitumumab. According to the guidelines, in the adjuvant setting for stage II or III patients with resectable CRC, regimens including 5-FU-based agents and leucovorin with or without oxaliplatin are recommended, and for stage IV patients with unresectable CRC, regimens including 5-FU-based agents and leucovorin with oxaliplatin or CPT-11 and the addition of bevacizumab, cetuximab or panitumumab are considered (2). Over the past two decades, there have been advances in the treatment of CRC; however, patients need novel strategies not only to enhance the efficacy of the above agents but also to utilize newly identified therapeutic targets.
Alternative precursor messenger RNA (pre-mRNA) splicing is the process by which the exons of pre-mRNA are spliced in different arrangements to produce structurally and functionally distinct mRNAs and proteins ( Figure 1A ) (3) . After the completion of the Human Genome Project in 2004, alternative splicing has been recognized as one of the most important mechanisms that maintains genomic and functional diversity. It is well known that >95% of human genes encode splice isoforms (4), some of which exert antagonistic functions. A recent study revealed that alterations of the splicing machinery can cause the development of myeloid neoplasms (5), and understanding the splicing machinery is crucial for the development of novel therapeutic strategies for malignancies. Another recent study revealed that a series of functionally associated splice isoforms are simultaneously expressed under a common regulatory network (6) , which supports the notion that an entire set of splice isoforms or their common regulatory network should be considered as therapeutic targets, rather than focusing on a single gene as a target. In this review, we summarize the current knowledge about the potential of using splice isoforms as therapeutic targets, focusing on CRC, and discuss the future work that needs to be done to develop therapeutic strategies targeting these splice isoforms.
Alternative pre-mRNA splicing
The first studies on pre-mRNA splicing were published in 1977 (7, 8) . Two regulatory factors have been the focus of most investigations related to the splicing machinery: cis-elements and trans-elements ( Figure 1A ). Among the cis-elements, consensus splice sites such as the 5′ splice site (5′SS; also known as a splice donor site), the branch point motif, the poly-pyrimidine tract [(Y)n] and the 3′ splice site (3′SS; also known as a splice acceptor site) are essential for pre-mRNA splicing. Splice enhancers and silencers are also categorized into ciselements, both of which are important for the recognition of the 5′SS and 3′SS sites. Depending on their localization within the genome, splice enhancers and silencers are subclassified into exonic splice enhancers (ESEs), intronic splice enhancers (ISEs), exonic splice silencers (ESSs) and intronic splice silencers (ISSs). Cis-elements are bound by trans-elements. Among the trans-elements, spliceosomes are multicomponent complexes comprising >200 subunits. Among the subunits of spliceosomes, serine-/arginine-rich proteins (SR proteins, SRp) predominantly bind to ESEs and ISEs; in contrast, heterogeneous nuclear ribonucleoproteins (hnRNPs) commonly bind to ESSs and ISSs. In many cases, hnRNPs block spliceosome assembly, resulting in exon skipping. Recently, tissue-or organ-specific SR proteins and hnRNPs have been extensively investigated (9, 10) . Figure 1B shows several patterns of alternative splicing in which splice isoforms are generated: (i) exon skipping in which an alternative exon is excluded or included, (ii) intron retention between constitutive exons, (iii) inclusion of one of the exons in a mutually exclusive manner, (iv) use of alternative 5′SSs, (v) alternative 3′SSs, (vi) alternative initiation sites and (vii) alternative polyadenylation sites.
The normal expression profile is indicated in the lower left panel, whereas the aberrant splicing that is observed in malignancies is shown in the lower right panel of Figure 1A , and can be subclassified into two categories: (i) aberrant splice isoforms as individual transcripts and (ii) an aberrant expression profile of splice isoforms as an entire set of transcripts; both of which occur at the germ cell or somatic cell level. Herein the word 'change' is used to encompass both 'genetic polymorphism' and 'genetic alterations'. The former category 'aberrant splice isoforms' can be caused by changes in the 5′-untranslated region (UTR), coding regions and 3′-UTR, as well as ESEs and ESSs, and altered expression of trans-elements may also cause aberrant splice isoforms. In contrast, the latter category 'aberrant expression profiles' can be caused by altered expression and structures of trans-elements, changes in the 5′-UTR, 3′-UTR, ESEs, ESSs, ISEs and ISSs, and possibly by changes of the consensus splice sites in introns. Recent evidence has demonstrated that most splicing occurs cotranscriptionally, and transcription modulates the splicing as well (11) . In the following sections, the potential use of splice isoforms as therapeutic targets for CRC, all of which were recently identified, is discussed.
Vascular endothelial growth factor
The vascular endothelial growth factor (VEGF) gene superfamily consists of at least six ligands, many of which are spliced to generate a multitude of ligand isoforms (12) . The VEGF molecules bind specifically to one or two of the three VEGF receptors (VEGFRs), with VEGFA binding to VEGFR-1 and VEGFR-2 (13). VEGFA and its receptors have been the most common research focus with regard to therapeutic targets with antiangiogenic effects. In addition to the previously known subfamily of VEGFA isoforms (VEGFAxxx), another subfamily, VEGFAxxxb, was identified in 2002 (14) . The terminal exon 8 of VEGFA gene is spliced in a mutually exclusive manner, resulting in a six amino acid substitution (CDKPRR to SLTRKD) to generate VEGFAxxx and VEGFAxxxb, respectively ( Figure 2A ). Recent studies have revealed the VEGFAxxx isoform to have proangiogenic properties, whereas VEGFAxxxb has antiangiogenic properties (15, 16) .
Bevacizumab (17), which was approved for clinical use against CRC in 2004, is a humanized monoclonal antibody that inhibits both the VEGFAxxx and VEGFAxxxb isoforms by blocking their common kinase domain receptor binding site (18) . Despite the effectiveness of bevacizumab when it is combined with cytotoxic agents, its low response rate, high rate of resistance and adverse events have been discussed (19) . These disadvantages of using bevacizumab may be caused by non-specific targeting, probably resulting from the non-specificity of the antibody for the pro-and antiangiogenic isoforms. In response to these findings, strategies specifically blocking the VEGFAxxx subfamily have been explored and pegaptanib was developed as a short modified RNA aptamer that specifically binds to VEGFAxxx but not VEGFAxxxb (20) . Another possible target for CRC is a trans-element, SRp55, which is known to increase VEGFAxxxb expression, leading to antiangiogenic effects (21) . In addition, IGF1, TNF-α and TGF-β1 were also identified as being involved in regulating the alternative splicing of VEGFA (21) .
UDP glucuronosyltransferase 1A1 and pregnane X receptor CPT-11, a semisynthetic camptothecin derivative that functions as a topoisomerase I-inhibitor, has been used as an effective anticancer prodrug against CRC. CPT-11 is anabolized to its active metabolite, SN-38, by carboxylesterase (22) , and catabolized to its inactive metabolite by glucuronidation (23) . UDP glucuronosyltransferase 1A1 (UGT1A1) is the main enzyme involved in glucuronidation of UDP, and genetic polymorphisms of this enzyme, such as UGT1A1*28 (leading to a TA insertion in the promoter region) (24) and single nucleotide polymorphisms (25, 26) , are known to affect its glucuronidation activity. However, it is widely recognized that the UGT1A1 activity cannot be explained by the polymorphisms alone. One of the main reasons may be the alternative splicing of the UGT1A gene. Based on a search of the National Center for Biotechnology Information (NCBI) database and a PubMed literature survey, at least nine isoforms, including UGT1A1, are generated by the alternative splicing of UGT1A ( Figure 2B ), among which UGT1A1, UGT1A7, UGT1A9 and UGT1A10 have glucuronidation activity (27, 28) , but some of the other isoforms are non-functioning. This means that controlling the alternative splicing of UGT1A is important to avoid or decrease the adverse effects associated with CPT-11 and to enhance its efficacy. Recently, Guillemette's group found that the UGT1A locus encodes a previously unknown splice isoform, UGT1A-i2, which is different from the previously known isoform, UGT1A-i1, which results from the alternative splicing of the terminal exon 5 (29) . They found that UGT1A-i1 has glucuronosyltransferase activity, but UGT1A-i2 is inactive. By an immunohistochemical analysis using antibodies specific for each of the isoforms, they revealed that UGT1A-i1 and UGT1A-i2 are coproduced in the same structural regions in various organs (30) . They further clarified that there is decreased expression of both UGT1A-i1 and UGT1A-i2 in CRC compared with corresponding normal tissues. Knockdown of endogenous UGT1A-i2 enhanced the cellular UGT1A-i1 activity (31) , which supports the notion that UGT1A-i2 has a dominant-negative function and is a potential target for regulating the efficacy of CPT-11.
In addition, the UGT1A1 activity is regulated by splice isoforms of the pregnane X receptor (PXR) gene, which encodes a xenoreceptor that regulates drug metabolism and transporter genes (32) . Currently, the PXR is known to have three major splice isoforms, T1, T2 and T3 ( Figure 2C ) (33) . The expression of UGT1A1 isoforms, as well as that of UGT1A3 and UGT1A4, is upregulated by the T1 and T2 isoforms, but not by T3, which indicates that splice isoforms of PXR are potential therapeutic targets that may regulate the efficacy of CPT-11. In contrast, CPT-11 treatment of HCT116 cells preferentially affected the alternative splicing of factors such as RBM8A, which was not observed in cells treated with cisplatin or vinblastine (34) . This indicates that the alternative splicing induced by CPT-11 was not simply due to reduced topoisomerase I activity, but rather was due to rapid RNA polymerase II hyperphosphorylation caused by CPT-11 (34) .
Cyclin D1
The cyclin family is composed of proteins that control the progression of the cell cycle by activating cyclin-dependent kinases (CDKs). Among them, the protein encoded by CCND1 (cyclin D1) forms a complex with CDK4 and CDK6. The cyclin D1-CDK4/CDK6 complex induces the phosphorylation of retinoblastoma protein, which releases transcription factors from the phosphorylation of retinoblastoma protein complex, thereby promoting cell division through the G 1 -S checkpoint (35) . For this reason, cyclin D1 has been regarded as a proto-oncogene and overexpression of cyclin D1 occurs at a high frequency in patients with CRC (36,37), esophageal cancer (38) and other malignancies. In addition, cyclin D1 can activate estrogen receptors in a CDK-independent manner in breast cancer (39) and an abundance of cyclin D1 affects the radiation sensitivity in some malignancies (40) . The transcriptional mechanisms and other functions of cyclin D1 have recently been analyzed (41) .
Although genetic alterations of the cyclin D1 locus are rarely observed, recent studies have demonstrated that the alternative splicing of cyclin D1 can influence the cancer risk and carcinogenesis (42) . The cyclin D1 gene is known to produce two alternative splice isoforms: CD1a and CD1b ( Figure 2D ). CD1a is a canonical isoform that consists of five exons, whereas CD1b includes exons 1-4 and a partial intron 4 (43) . In colon cancer and other malignancies, the single nucleotide polymorphism G870A, which is the last nucleotide of exon 4 (CCG and CCA) and is located adjacent to the 5′SS of intron 4 (GURAGU in Figure 1A ), modulates the alternative splicing between exon 5 and intron 4, thus generating CD1a and CD1b, respectively (44) . In addition, trans-elements ASF/SF2 (45) and Sam68 (46) regulate the alternative splicing toward the generation of CD1b. Although both CD1a and CD1b can associate with CDK4 and CDK6, they show distinct functions and cellular localizations. Phosphorylation of Thr286, which is located within exon 5 ( Figure 2D ), allows for the nucleocytoplasmic translocalization of cyclin D1 and its subsequent degradation (47); hence, CD1a can translocate to the cytoplasm, whereas CD1b remains constitutively in the nucleus. Although such functions of CD1a have not been observed, CD1b can cause cellular transformation and has been linked to human carcinogenesis (42, 47) . By performing the immunocytochemical analyses using antibodies for each of the isoforms, Li et al. (40) showed that CD1a, but not CD1b, elicited the DNA damage response in colon cancer cells when stably associated with chromatin. Considering the above results, the two splice isoforms of cyclin D1 must be distinguished in order to develop therapeutic strategies targeting cyclin D1, and CD1b should be targeted for downregulation to maintain the inherent cell cycle control.
Baculoviral inhibitor of apoptosis protein repeat-containing 5 (survivin)
The inhibitor of apoptosis protein (IAP) family, which is characterized by the presence of baculovirus IAP repeat (BIR) domains (48, 49) , prevents apoptosis through direct inhibition of caspases and procaspases, and these proteins are expressed at elevated levels in the majority of human malignancies (50) . Currently, seven genes in the IAP family have been isolated, among which the baculoviral IAP repeatcontaining 5 (BIRC5) gene, also known as survivin, has been the most investigated as a therapeutic target for malignancies, and novel agents targeting this gene or protein are currently under development. Among them, YM155 (Astellas Pharma, Tsukuba, Japan) is a small molecule inhibitor of survivin (51) . In 2012, Nakamura et al. (51) revealed that YM155 suppresses the expression of survivin through binding to the C-terminal region of interleukin enhancer-binding factor 3, although their study on the molecular mechanism is still underway. LY2181308 (Eli Lilly and Co., Indianapolis, IN) is a second-generation antisense oligonucleotide with a phosphorothioate backbone and other structural modifications, which targets the translation initiation site of the survivin transcripts (52) . Both of these agents are designed to block all of the survivin transcripts. Recently, amiloride was reported to regulate the alternative splicing of survivin, as well as that of APAF1 and CRK (53) .
Several splice isoforms of survivin have been reported ( Figure 2E ). In 2007, Sampath and Pelus (54) published a detailed review on the splice isoforms of survivin. The splice isoform Sur2B was regarded to be proapoptotic until the middle of the 2000s. However, the results of recent studies in CRC (55) and other malignancies (56,57) indicated different outcomes. In 2010, Sawai et al. (55) reported that Sur2B expression in CRC is an important factor involved in the invasive capacity of tumors in the presence of 5-FU. In 2011, Huang et al. (56) reported that the SurWT, Sur-DeltaEx3 and Sur2B isoforms were significantly elevated in astrocytoma and were associated with a poorer prognosis and Vivas-Mejia's study on ovarian cancer cells showed that Sur2B was more abundant in taxane-resistant cells than in taxane-sensitive cells (57) . Using CRC samples and corresponding normal tissues, Pavlidou et al. (58) analyzed the expression levels of the isoforms, and Antonacopoulou et al. (59) analyzed the correlation between the expression of survivin isoforms and single nucleotide polymorphisms. It is still difficult to integrate all of the information on the survivin isoforms because some of the results have been contradictory, but the information will be important to design therapeutic strategies targeting survivin.
Dihydropyrimidine dehydrogenase
After its development in 1957 (60), 5-FU has been a core anticancer agent used for CRC. Approximately 90% of the administered 5-FU is catabolized by dihydropyrimidine dehydrogenase (DPD), mainly in the liver, whereas the remaining 10% of 5-FU is anabolized to exert cytotoxic activity (61) , making DPD the most important determinant of 5-FU metabolism (62) . Screening for genetic alterations with genomic DNA and mRNA sequencing, van Kuilenburg et al. (63) identified genetic alterations in deep intronic regions such as c.1129-5923C>G, which caused aberrant splice isoforms of the DPD gene. Their study indicates that caution should be exercised when screening for introns, as well as for exons, when identifying DPD-deficient patients and determining the likely efficacy of 5-FU.
Other splice isoforms implicated in CRC
Some of the other genes encoding splice isoforms that may be possible therapeutic targets for CRC are the K-RAS (64), macroH2A1 (65, 66) , SOX9 (67), SLC39A14 (68,69), colorectal neoplasia differentially expressed (CRNDE) (70), BARD1 (71), CDH17 (72), CYP24A1 (73) and PPARG genes (74) . It is well known that somatic mutation of the K-RAS gene is an early event in colorectal carcinogenesis. However, since the middle of the 2000s, the splice isoforms K-RAS4A and K-RAS4B have been reported to have differential functions in apoptosis (75) and differentiation (76) in the intestinal epithelia. In 2009, Abubaker et al. (64) analyzed CRC tissues for somatic mutations in the K-RAS gene, as well as performing an immunohistochemical analysis of the splice isoforms. Their study demonstrated that the expression of K-RAS4A and K-RAS4B was associated with several clinicopathological features of CRC, and both the K-RAS mutation and K-RAS4A expression were independent prognostic markers in a multivariate analysis.
MacroH2A1 is the founding member of the macroH2As family, which has the ability to replace the functions of canonical histones, and has two splice isoforms: macroH2A1.1 and macroH2A1.2. In 2011, Novikov et al. (65) demonstrated that the expression of macroH2A1.1 is suppressed in CRC and other malignancies compared with normal tissues. An immunohistochemical study of the two isoforms by Sporn et al. (66) in 2012 revealed that the loss of macroH2A1.1 was associated with a worse prognosis of CRC.
The SOX9 transcription factor, which has antioncogenic potential in CRC, generates two isoforms: canonical SOX9 and MiniSOX9, which is a truncated isoform of SOX9 expressed at high levels in CRC (67) . An immunohistochemical analysis of CRC and corresponding normal tissues using isoform-specific antibodies revealed that MiniSOX9 behaves as a SOX9 inhibitor and increases the oncogenic potential of CRC cells (67) . This indicates that MiniSOX9 may be a therapeutic target for CRC.
SLC39A14 is a divalent cation transporter, which consists of nine exons and has two splice isoforms with a mutually exclusive exon 4, which generates two isoforms: SLC39A14-4A and SLC39A14-4B. In 2011, Thorsen et al. (69) demonstrated that SLC39A14-4B mRNA is highly expressed in colonic adenoma and CRC tissues compared with the SLC39A14-4A mRNA. In 2011, Sveen et al. (68) reported that SLC39A14-4B can be used as a marker to distinguish CRC from other pathological conditions of the colon. In addition, Graham et al. (70) indicated that splice isoforms of the CRNDE gene seem to be differentially expressed in different stages of CRC.
In 2011, Yi and Tang reported a review article on the potential use of splice variants as diagnostic, predictive and prognostic markers for CRC (77) , which included information about APC, TIMP-1, VEGFA, DYX1C1 and c-FLIP, among other genes. Their article provided information about the splice isoforms with regard to the use of chemotherapy for CRC. A genome-wide exon array analysis in 2011 detected several CRC-specific splice isoforms (TCF12, OSBPL1A, TRAK1, ANK3, CHEK1, UGP2, LMO7, ACSL5 and SCIN) (78) . In addition, trans-elements, such as SR protein kinase 1 and SR protein kinase 2, have also been discussed as therapeutic targets for CRC and other malignancies (79) , although trans-elements are not described in detail in this review. Most of the studies presented here were reported after 2011, and the information on splice isoforms is still being accumulated.
Therapeutic strategies to target splice isoforms
Therapeutic targeting of splice isoforms may be achieved through conventional small molecules, but these molecules can only target a small subset of proteins, such as enzymes (e.g. tyrosine kinases) and receptors (e.g. the epidermal growth factor receptor). On the other hand, RNA-based therapeutics can theoretically target all of the premRNAs and mRNAs with a wider range and higher selectivity than small molecules (80) , although almost all of these modalities are still in preclinical development. Currently, the most important issue to be resolved for the use of RNA-based therapeutics as macromolecules is the development of an optimal drug delivery system.
The RNA-based therapeutics include antisense oligonucleotides, small interfering RNA (siRNA), splice-switching oligonucleotides and other molecules such as ribozymes and aptamers. Among them, synthetically modified antisense oligonucleotides are about 20 nucleotides long ( Figure 3A ) and the annealing of the oligonucleotides to mRNA allows the cleavage of the mRNA by ribonuclease H. To provide enhanced structural stability and pharmacological qualities while not interfering with the activity of ribonuclease H, various modifications of their chemical structures have been made, such as the use of a phosphorothioate linkage instead of natural phosphates as a backbone of nucleotides, and 2′-O-methyl (2′-OMe) residues, 2′-O-methoxyethyl (2′-MOE) residues or locked nucleic acids (81) have also been developed. In addition, the chemistry-dependent toxicities induced by their structures is another important issue to be considered. siRNA ( Figure 3B ) is another modality that consists of a double-stranded RNA fragment 21-22 nucleotides long. After interacting with the multiprotein RNA-induced silencing complex, the antisense strand of the siRNA anneals to the complementary mRNA as a target, and the endonuclease argonaute 2 cleaves the annealed mRNA. In this modality, off-target effects and the innate immune response via the activation of Toll-like receptors should be carefully managed. Splice-switching oligonucleotides ( Figure 3C ) modulate pre-mRNA splicing with spliceosomes and repair the defective premRNA to generate proteins that have distinct functions. Monoclonal antibodies (82) have also been used for various targets ( Figure 3D ). In contrast with the RNA-based therapeutics, some antibodies targeting oncogenic proteins have already been in clinical use; and those for each of the splice isoforms will likely be further developed for clinical use. The development of antibodies is still very expensive, and further considerations for their development are discussed elsewhere (83) . Targeting trans-elements that act as spliceosomes or splicing modulators is another option.
Future perspectives
In this review, we summarized the splice isoforms that represent possible therapeutic targets for CRC. As discussed in this review, isoform-specific antibodies for VEGFA (16) , UGT1A (30), cyclin D1 (40), K-RAS (64) and SOX9 (67) are currently available, and they can be utilized for immunohistochemical analyses and other purposes, and may eventually be useful for clinical applications. With the recent advances in nucleotide sequencing technologies, an entire set of genomic DNA sequences has been analyzed, and in the next stage, an entire set of RNA sequences will be further analyzed; the interpretation of the latter, however, is far more complex compared with the former, mainly due to the wide variety of mature mRNAs resulting from alternative splicing. To elucidate the regulatory mechanism(s) for alternative splicing as a whole, the two sets of sequence information will have to be integrated. Although the importance of individual cis-elements in the splicing machinery has been widely discussed, the concept of a 'splicing code', which is defined as a complex combination of the cis-elements that direct constitutive or alternative splicing, was proposed as early as the 1970s. To experimentally prove this concept had been a major challenge, but recent studies combining transcriptome-wide data with advanced machine learning algorithms were able to predict new classes of alternative splicing events under regulation by the splicing code (84, 85) . Furthermore, in a recent genome-wide siRNA screening, Moore et al. (6) identified a coordinated alternative splicing of Bcl-X, MCL1, CASP9 and other apoptosis-associated genes under a common regulatory network. These findings suggest that we should consider a set of splice isoforms or their common regulatory network when developing therapeutic strategies for malignancies, rather than targeting a single gene. To what extent the mechanisms regulating alternative splicing are organ-specific remains unclear, but the phenomenon is complex, and is the subject of many ongoing studies.
Research in these various areas is still ongoing, and new discoveries are being reported at a rapid pace. Recent reports have demonstrated that alternative splicing is also affected by newly identified regulatory factors, such as RNA polymerase II elongation (86), the chromatin structure (87, 88) , histone modifications (89), the RNA structure (90) and the spliceosome structure (91), most of which are interwoven bidirectionally (87, 88) . Importantly, the splicing machinery is regulated by innate microRNAs, siRNAs, small nucleolar RNAs and other non-coding RNAs (92, 93) , and these should also be considered as therapeutic targets. The rapidly increasing information available about nucleotide sequences, trans-elements, and newly identified regulatory factors, along with novel bioinformatics technology, such as the multimapping Bayesian gene eXpression (MMBGX) program by Turro et al. (94) , which enables the detection of differential splicing at the isoform level, will provide additional information about how therapeutic strategies targeting alternative splicing in malignancies can be developed.
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